UY35624A - Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington - Google Patents

Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Info

Publication number
UY35624A
UY35624A UY35624A UY35624A UY35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A
Authority
UY
Uruguay
Prior art keywords
disease
pridopidine
high dose
treat huntington
huntington
Prior art date
Application number
UY35624A
Other languages
English (en)
Spanish (es)
Inventor
Bassan Merav
Esther Lukasiewicz Hagai
Eyal Eli
Anna Kristina Sveinsdotter Teige Wickenberg
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of UY35624A publication Critical patent/UY35624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY35624A 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington UY35624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
UY35624A true UY35624A (es) 2015-01-30

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35624A UY35624A (es) 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Country Status (24)

Country Link
US (1) US10322119B2 (enExample)
EP (1) EP3010506B1 (enExample)
JP (1) JP2016523862A (enExample)
KR (1) KR102316933B1 (enExample)
CN (1) CN105592848A (enExample)
AU (1) AU2014281414A1 (enExample)
BR (1) BR112015029918A2 (enExample)
CA (1) CA2913781C (enExample)
CL (1) CL2015003690A1 (enExample)
DK (1) DK3010506T3 (enExample)
EA (1) EA201690069A1 (enExample)
ES (1) ES2879631T3 (enExample)
HK (1) HK1221646A1 (enExample)
HU (1) HUE054783T2 (enExample)
IL (1) IL242804B (enExample)
MX (1) MX384234B (enExample)
PE (2) PE20170302A1 (enExample)
PH (1) PH12015502691A1 (enExample)
PL (1) PL3010506T3 (enExample)
SG (1) SG11201509729YA (enExample)
TW (1) TW201529069A (enExample)
UA (1) UA122999C2 (enExample)
UY (1) UY35624A (enExample)
WO (1) WO2014205229A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
CN110012661A (zh) * 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
AU2017326436A1 (en) * 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
US20260091028A1 (en) * 2017-08-14 2026-04-02 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
HUE061505T2 (hu) * 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) * 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
SMT202600016T1 (it) * 2019-06-12 2026-03-09 Prilenia Neurotherapeutics Ltd Composizione contenente pridopidina e un suo analogo per il trattamento della malattia di huntington e dei suoi sintomi
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
CA3214354A1 (en) * 2021-04-14 2022-10-20 Michael Hayden Treatment of prodromal huntington disease
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
KR102316933B1 (ko) 2021-10-26
ES2879631T3 (es) 2021-11-22
CA2913781C (en) 2022-05-10
EP3010506B1 (en) 2021-05-12
HK1221646A1 (zh) 2017-06-09
JP2016523862A (ja) 2016-08-12
DK3010506T3 (da) 2021-07-12
WO2014205229A1 (en) 2014-12-24
US20140378508A1 (en) 2014-12-25
CL2015003690A1 (es) 2016-10-28
HUE054783T2 (hu) 2021-09-28
UA122999C2 (uk) 2021-02-03
WO2014205229A8 (en) 2015-04-09
IL242804B (en) 2022-02-01
CN105592848A (zh) 2016-05-18
MX2015017307A (es) 2016-08-03
PL3010506T3 (pl) 2021-11-02
CA2913781A1 (en) 2014-12-24
EP3010506A4 (en) 2017-02-08
AU2014281414A1 (en) 2016-01-21
KR20160055122A (ko) 2016-05-17
BR112015029918A2 (pt) 2017-07-25
SG11201509729YA (en) 2015-12-30
US10322119B2 (en) 2019-06-18
EA201690069A1 (ru) 2016-06-30
PE20170302A1 (es) 2017-03-31
TW201529069A (zh) 2015-08-01
EP3010506A1 (en) 2016-04-27
PE20160195A1 (es) 2016-05-14

Similar Documents

Publication Publication Date Title
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
TN2015000505A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
ZA202000028B (en) Use of vibegron to treat overactive bladder
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
AR082645A1 (es) Composiciones y metodos para tratar sindrome mielodisplasico
AR059219A1 (es) Uso de la suramina para la preparacion de un medicamento para inhibir la neovascularizacion retinal y corneal

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206